MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`ORIGINAL
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICAL INC.,
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-00200
`Patent 8,603,514 B2
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PAR PHARMACEUTICAL, INC. AND INTELGENX CORP.,
`Petitioners,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01557
`Patent 8,603,514
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`DR. REDDY'S LABORATORIES S.A. and DR. REDDY'S
`LABORATORIES, INC.
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01582
`Patent 8,603,514
`
`PATENT TRIAL AND APPEAL BOARD HEARING
`
`Before Gina L. Smith, Certified Court Reporter
`
`Reported Telephonically
`
`On October 4, 2017, Commencing at 12:00 p.m.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0001
`
`
`Hearing on 10/04/2017
`
`ORIGINAL
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICAL INC.,
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-00200
`Patent 8,603,514 B2
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`PAR PHARMACEUTICAL, INC. AND INTELGENX CORP.,
`Petitioners,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01557
`Patent 8,603,514
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`DR. REDDY'S LABORATORIES S.A. and DR. REDDY'S
`LABORATORIES, INC.
`Petitioner,
`v.
`MONOSOL RX, LLC,
`Patent Owner.
`
`Case IPR2017-01582
`Patent 8,603,514
`
`PATENT TRIAL AND APPEAL BOARD HEARING
`
`Before Gina L. Smith, Certified Court Reporter
`
`Reported Telephonically
`
`On October 4, 2017, Commencing at 12:00 p.m.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0001
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 2
`
`1
`
`MR. HAROLD FOX: Good afternoon, Your Honor. This
`
`2 is Harold Fox, lead counsel for Monosol in the three
`
`3 named IPR's. We do have a court reporter on the line.
`
`4 With me I have Dustin Weeks and Sharon Broma who are
`
`5 co-counsel, back-up counsel, on the 200 proceedings.
`
`6
`
`JUDGE FRANKLIN: And you are willing to
`
`7 participate in this combined call?
`
`8
`
`9
`
`MR. HAROLD FOX: Yes.
`
`JUDGE FRANKLIN: And also I'm going to ask that
`
`10 you file a copy of the transcript when it's available.
`
`11
`
`12
`
`13
`
`MR. HAROLD FOX: We will do so.
`
`JUDGE FRANKLIN: And, Petitioner Mylan.
`
`MR. STEVE PARMELEE: Good afternoon, Your Honor.
`
`14 This is Steve Parmelee, lead counsel for Petitioner
`
`15 Mylan Technologies, Inc. And we're here on the 2017-
`
`16 00200 and I guess the--I'm not sure if the other case
`
`17 is also involved in this call. My impression is it is
`
`18 not so we do not have a court reporter. We're willing
`
`19 to participate to the extent that this involves the
`
`20 termination discussion, termination of our proceeding,
`
`21 and that's the limited nature of our appearance this
`
`22 afternoon.
`
`23
`
`JUDGE FRANKLIN: And to clarify, the parties
`
`24 invited to this call are parties for your proceeding,
`
`25 IPR200 but also IPR2017-01557 and 01582. So having
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0002
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 3
`
`1
`
`2
`
`their participation in the call along with you and your
`
`case is what I'm seeking confirmation of whether you
`
`3
`
`agree or are willing to have this combined call.
`
`4
`
`5
`
`6
`
`MR. STEVE PARMELEE: Yes, Your Honor.
`
`JUDGE FRANKLIN: Thank you. And, Petitioner Par?
`
`MR. JONATHAN STRANG: Good morning, Your Honor.
`
`7 This is Jonathan Strang, counsel for Petitioner Par.
`
`8 And with me today I have Brenda Danek We do not have
`
`9 a court reporter. Patent Owner indicated it will file
`
`10 the transcript, and we do not object to the combined
`
`11 call.
`
`12
`
`JUDGE FRANKLIN: Thank you. And can you spell
`
`13 your last name for me.
`
`14
`
`MR. JONATHAN STRANG: Yes, Your Honor. S-T-R-A-N-
`
`15 G.
`
`16
`
`JUDGE FRANKLIN: Thank you. Petitioner Dr.
`
`17 Reddy's.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`MR. IRA LEVY: Good afternoon, Your Honor. It is
`
`Ira Levy from Goodwin on behalf of Dr. Reddy's in
`
`IPR2017-01582. I am joined by my colleague Robert
`
`Frederickson, who has not appeared but will be
`
`appearing in the proceedings and we agree to join the
`
`joint call. And similar to Par, we understand that
`
`Patent Owner has a court reporter and will be filing
`
`25
`
`the transcript.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0003
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 4
`
`1
`
`JUDGE FRANKLIN: Okay. Thank you all for that.
`
`2
`
`Before I talk to Par and Dr. Reddy's, the Petitioners
`
`3
`
`who urgently asked for this conference call, I'd like
`
`4
`
`to direct one question to Petitioner Mylan, Petitioner
`
`5
`
`of the 200IPR, a point of clarification.
`
`It seems that at least in one, perhaps in both,
`
`7
`
`with respect to the joinder in both 1557 and 1582 you
`
`8 may have indicated you do not oppose. We understand
`
`9 that Mylan and Monosol have reached a settlement in
`
`10 IPR200 and that as authorized have filed a motion to
`
`11 terminate that proceeding. In view of that settlement
`
`12 and that filing, does Mylan oppose the joinder request
`
`13 in 1557 and 1582?
`
`14
`
`MR. STEVE PARMELEE: Your Honor, we're here to
`
`15 talk about the termination of this 200 case. Our
`
`16 position has not changed on those joinders cases
`
`17 themselves.
`
`18
`
`JUDGE FRANKLIN: Okay. What I'm asking is for you
`
`19 to clarify then. You're telling us that you do not
`
`20 oppose joinder of 1557 and 1582 with you in the IRP200.
`
`21
`
`MR. STEVE PARMELEE: Well, we'd like to have this
`
`22 proceeding terminated. And what Your Honor does with
`
`23 the other cases and how they are treated doesn't
`
`24 necessarily turn on termination here.
`
`25
`
`JUDGE FRANKLIN: Correct. I just wanted to ask
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0004
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 5
`
`1 this one more time. This is for my clarification. I
`
`2 want to know your position. Apart from termination, do
`
`3 you have any issue with joinder with Par and Dr.
`
`4 Reddy's in the IPR200?
`
`5
`
`MR. STEVE PARMELEE: Our position is the same as
`
`6 we previously stated. We don't have an issue with the
`
`7 joinder petitioners or petitions, but we do want our
`
`8 proceeding terminated. We don't want responsibility for
`
`9 the IPR200 as it goes forward or if it is to go
`
`10 forward.
`
`11
`
`JUDGE FRANKLIN: Okay. And, Patent Owner, I think
`
`12 I understand from an email that you sent your position,
`
`13 but I want to give you an opportunity to respond to the
`
`14 same question.
`
`15
`
`MR. HAROLD FOX: Your Honor, this is Harold Fox.
`
`16 Dustin Weeks will be presenting for Patent Owner and
`
`17 can address that point.
`
`18
`
`MR. DUSTIN WEEKS: Yes, Your Honor, this is Dustin
`
`19 Weeks for Patent Owner. Patent Owner does oppose
`
`20 joinder of both--of Dr. Reddy's and Par in this case.
`
`21 And while we have not filed an opposition to the motion
`
`22 for joinder for Par, I guess depending on how this call
`
`23 goes today, Patent Owner would ask for authorization to
`
`24 submit additional briefing in both cases opposing
`
`25 joinder, given the change in circumstances due to the
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0005
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 6
`
`1
`
`2
`
`settlement with Mylan.
`
`JUDGE FRANKLIN: Okay. Thank you. Now let's turn
`
`3
`
`to Petitioners Par and Dr. Reddy's. Before I give an
`
`4
`
`opportunity to further explain your request I would
`
`5
`
`like to start with the question of, is your basis for
`
`6 wanting to oppose the motion to terminate an IPR200
`
`7 only as to its timing?
`
`8
`
`MR. JONATHAN STRANG: There's actually two aspects
`
`9 of that, Your Honor. Pardon me, this is Jonathan Strang
`
`10 for Petitioner Par and so the record--to make it clear
`
`11 for the record, we've coordinated with Dr. Reddy's and
`
`12 they're going to stay in the understudy role that they
`
`13 said they'd stay in in their motion for joinder. So,
`
`14 although they can speak up if they have any issues that
`
`15 affect only them.
`
`16
`
`And to answer your question, Your Honor, we oppose
`
`17 it only as to the Patent Owner. And as far as the
`
`18 timing goes, that is correct. Under Section 317 the
`
`19 Board has discretion to keep the IPR pending as to the
`
`20 Patent Owner and doesn't have that same discretion for
`
`21 the original petitioners. So Mylan is off the hook
`
`22 here. Our position is that the--we would like the Board
`
`23 to exercise its discretion that the Congress gave it to
`
`24 either hold the motion in abeyance or partially grant
`
`25 the motion to terminate, excusing Mylan from any
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0006
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 7
`
`1 further participation.
`
`2
`
`JUDGE FRANKLIN: And what is your basis for making
`
`3 that request?
`
`4
`
`MR. JONATHAN STRANG: Your Honor, well, the motion
`
`5 for joinder that we timely filed I think lays out the
`
`6
`
`reasons that joinder is appropriate here. It's the same
`
`7
`
`petition. We essentially copied in the same evidence,
`
`8
`
`the same expert. And as far as experts go, it isn't
`
`9
`
`clear from the public record so we don't know but if
`
`10
`
`we--a deposition after the Patent Owner's response has
`
`11 already occurred. If we're given a transcript of that
`
`12 we'll take that transcript and fold right into the
`
`13 schedule and file a reply in accordance with whatever
`
`14 schedule the Board grants so all the factors for
`
`15
`
`16
`
`17
`
`18
`
`19
`
`joinder are met. So what we're asking the Board here to
`
`do is actually exercise its discretion and hold the
`
`decision as to Patent Owner either in abeyance or to
`
`deny it. And we think the best reason for that is the
`
`public interest and having this meritorious challenge
`
`20
`
`to this patent continue.
`
`21
`
`JUDGE FRANKLIN: Okay. Thank you. And Mr. Levy,
`
`22
`
`did you want to add anything to Mr. Strang's comments?
`
`23
`
`24
`
`25
`
`MR. IRA LEVY: No, Your Honor. We join those
`
`comments that the Board does in fact have discretion
`
`and it has in fact exercised that discretion in other
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0007
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 8
`
`1 proceedings where it has, for example, continued IPR's
`
`2 on its own and then granted a petition for joinder. But
`
`3 continuing in that understudy role that we committed
`
`4 to, we agree and join with those arguments.
`
`5
`
`JUDGE FRANKLIN: And, Mr. Fox, would you like to
`
`6 respond?
`
`7
`
`MR. DUSTIN WEEKS: Your Honor, this is Dustin
`
`8
`
`Weeks for Patent Owner. I'll respond on behalf of
`
`9 Patent Owner, if that's okay.
`
`10
`
`11
`
`JUDGE FRANKLIN: Yes.
`
`MR. DUSTIN WEEKS: So Patent Owner doesn't believe
`
`12 the Board should hold any decision on this one motion
`
`13 to terminate in abeyance. Mylan and Monosol which are
`
`14 the parties in IPR200 have reached a settlement.
`
`15 They've resolved all issues between them. They've
`
`16 subsequently taken the appropriate action to terminate
`
`17 the proceeding, so Patent Owner would submit that the
`
`18 Board can now act on that motion in its entirety rather
`
`19 than prejudice either of these parties by holding the
`
`20 future of that case undecided.
`
`21
`
`We'll also note that both Par and Dr. Reddy's
`
`22 waited more than seven months after the Mylan petition
`
`23 before filing their own petition and because of their
`
`24 delay the Board's decision on the institution of those
`
`25 two cases isn't due until late December, and the
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0008
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 9
`
`1 current Mylan IPR for the due dates one and two have
`
`2 already passed, even though Mylan did not file a
`
`3 petition or reply on due date two. And by the time of
`
`4 the institution decision--or by the time the due date
`
`5 from the institution decisions in the Par and Dr.
`
`6 Reddy's IPR's each of due dates one through six and the
`
`7 Mylan IRP will have already passed and the oral hearing
`
`8
`
`will be just a few weeks later on January 10th. So if
`
`9 the Board decides--if it decides to wait on deciding
`
`10 the motion to terminate and then for some reason it
`
`11 ultimately joins Par and Dr. Reddy's, which Patent
`
`12 Owner opposes, then significant changes would need to
`
`13 be made to the scheduling order.
`
`14
`
`Patent Owner would also like to mention the Board
`
`15 shouldn't be forced to rush and consider the
`
`16 preliminary responses filed by Patent Owner to Dr.
`
`17 Reddy and the Par cases, but proposes preliminary
`
`18 responses presented in the arguments that weren't
`
`19 previously considered by the Board when instituting the
`
`20 Mylan IPR, the additional delay in resolving the Mylan
`
`21 IPR, which Par and Dr. Reddy's are now requesting will
`
`22 prejudice Patent Owner. And as I'm sure the Panel is
`
`23 aware, the Board has recently taken a strong stance
`
`24 against this harassment for follow-on petitions and
`
`25 repeated attacks against the same patent with this
`
`800-333-2082
`Huseby, Inc. Regional Centers
`vvww. huseb y. c o m
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0009
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 10
`
`1 General Plastics decision which was issued early
`
`2 September, and then the two subsequent decisions just
`
`3 last week in the Alere case and the Parrot case. For
`
`4 those reasons we would ask the Board to go ahead and
`
`5 decide the motion to terminate and not to delay this
`
`6 case any further.
`
`7
`
`JUDGE FRANKLIN: Okay. So I'd like to go through
`
`8 and allow the Petitioners in each party an additional
`
`9
`
`comment if they have one, beginning with counsel for
`
`10
`
`Mylan.
`
`11
`
`MR. STEVE PARMELEE: Thank you, Your Honor, I just
`
`12
`
`would say that we agree with Mr. Weeks' comments to the
`
`13
`
`14
`
`extent they address the termination of the Mylan
`
`Monosol IPR's specifically. And other than that we have
`
`15
`
`no further comments. Thank you.
`
`16
`
`17
`
`JUDGE FRANKLIN: And Mr. Strang.
`
`MR. JONATHAN STRANG: Yes, Your Honor, thank you.
`
`18 Just two followup. Some cases where the Board has seen
`
`19 similar situations is Microsoft v. Windy City in
`
`20 IPR2016-01155 and there the Board exercises discretion
`
`21 under 317, to only granting part. And likewise in ATT
`
`22 v. Convergent and that's IPR2017-01237, almost exactly
`
`23 the same facts as here. And, again, the Board went
`
`24 ahead and granted joinder.
`
`25
`
`I'm hearing Patent Owners' complaints about
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0010
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 11
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`scheduling but really the only delay in schedule here
`
`is going to be due to Patent Owner insisting on an
`
`opposition, and their time to oppose this motion for
`
`joinder passed long ago. And, in fact, they also
`
`opposed it in the Patent Owner preliminary response
`
`that was just filed.
`
`And in response to the points about General
`
`Plastics, well, that case just isn't really applicable
`
`here, Your Honor, because it's about serial petitions
`
`10
`
`and the unfairness in each petitioner picking up what
`
`11
`
`has been decided before and adding a little bit more
`
`12
`
`13
`
`14
`
`15
`
`and adding a little bit more until the Patent Owner has
`
`just been overwhelmed with all these different
`
`responses. In this case it's no difference for the
`
`Patent Owner regardless. The POR has already been
`
`16 filed. All we're going to do is file a petition of
`
`17 reply and go to oral argument, other than some motions
`
`18 practice.
`
`19
`
`And as far as the schedule goes, this case isn't
`
`20 exactly as Patent Owner noted in its argumentative
`
`21 email to the Board. All the facts are in front of the
`
`22 Board that are needed to decide this same petition as
`
`23 before. Patent Owner asked to file a sur-reply to the
`
`24 motion for joinder, which doesn't really make sense
`
`25 because a sur-reply would be our--which doesn't really
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0011
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 12
`
`1 make sense because they didn't oppose it. But, like
`
`2 said, they've already opposed it in the Patent Owner
`
`3 preliminary response. There's no need for any further
`
`4 briefing.
`
`5
`
`Subject to any questions, Your Honor, Petitioner
`
`6 Par doesn't have anything else.
`
`7
`
`JUDGE FRANKLIN: Thank you. And then I assume, Mr.
`
`8 Levy, you join in what Mr. Strang has said without
`
`9 further comment?
`
`10
`
`11
`
`MR. IRA LEVY: Yes, we do, Your Honor.
`
`JUDGE FRANKLIN: Okay. If the parties can please
`
`12 hold, I'm going to confer with my panel. I'll be back
`
`13 momentarily.
`
`14
`
`15
`
`[Off record 12:16 p.m. to 12:21 p.m.]
`
`JUDGE FRANKLIN: We were holding. I just want to
`
`16 confirm that we still have all the parties on the line.
`
`17 If you could just indicate yes when I call your name.
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Harold Fox and Mr. Weeks.
`
`MR. HAROLD FOX: Yes.
`
`MR. DUSTIN WEEKS: Yes, Your Honor.
`
`JUDGE FRANKLIN: Thank you. Mr. Parmelee.
`
`MR. STEVE PARMELEE: Yes, Your Honor.
`
`JUDGE FRANKLIN: Mr. Strang.
`
`MR. JONATHAN STRANG: Yes, Your Honor.
`
`JUDGE FRANKLIN: And Mr. Levy.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0012
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 13
`
`MR. IRA LEVY: Yes, Your Honor.
`
`JUDGE FRANKLIN: Great. Thank you. I've conferred
`
`with the panel. We're going to take the matter under
`
`advisement. We will have an order for you shortly
`
`indicating how we'll resolve the issues raised today.
`
`If there's nothing further, we will adjourn. Thank you.
`
`[Hearing adjourns at 12:20 p.m.]
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8 //
`
`9 //
`
`10 //
`
`11 //
`
`12 //
`
`13 //
`
`14 //
`
`15 //
`
`16 //
`
`17 //
`
`18 //
`
`19 //
`
`20 //
`
`21 //
`
`22 //
`
`23 //
`
`24 //
`
`25 //
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC New York Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0013
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 14
`
`DISCLOSURE
`
`1
`
`2
`
`3 STATE OF GEORGIA
`
`4 COUNTY OF RICHMOND
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Pursuant to Article 10.B of the Rules and
`
`Regulations of the Board of Court Reporting of the
`
`Judicial Council of Georgia, I make the following
`
`disclosure:
`
`I am a Georgia Certified Court Reporter I am
`
`here as a representative of Prestige Reporting, LLC.
`
`Prestige Reporting was contacted to provide court
`
`reporting services for the deposition. Prestige
`
`Reporting will not be taking this deposition under any
`
`contract that is prohibited by O.C.G.A. Sec. 15-14-
`
`37(a) and (b).
`
`Prestige Reporting has no contract/agreement to
`
`provide reporting services with any party to the case,
`
`any counsel in the case, or any reporter or reporting
`
`agency from whom a referral might have been made to
`
`cover this deposition. Prestige Reporting will charge
`
`its usual and customary rates to all parties in the
`
`case, and a financial discount will not be given to any
`
`party to this litigation.
`
`Dated: 10/04/17; GINA L. SMITH, CCR, CVR-M, B-2151
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0014
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`
`Page 15
`
`1
`
`CERTIFICATE
`
`2 STATE OF GEORGIA:
`
`3 COUNTY OF RICHMOND:
`
`I hereby certify that the foregoing transcript was
`
`taken down, as stated in the caption, and the colloquy,
`
`questions, and answers thereto were reduced to
`
`typewriting under my direction; that the foregoing
`
`pages 2 through 13 represent a true, complete, and
`
`correct transcript of the evidence given.
`
`I further certify that I am not related to or are
`
`of counsel to the parties in the case; am not in the
`
`regular employ of counsel for any of said parties; nor
`
`am I in any way interested in the result of said case.
`
`This, the 6th day of October, 2017.
`
`• of
`
`GINA L. SMITH, CCR, CVR-M, B-2151
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19 //
`
`20 //
`
`21 /7
`
`22 //
`
`23 /7
`
`24 //
`
`25 //
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0015
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: 00200-City
`
`0
`
`act
`
`8 : 18
`
`action
`
`8 : 16
`
`argument
`11 : 17
`
`00200
`
`2 : 16
`
`add 7 : 22
`
`01582
`
`2 : 25
`
`1
`
`10th 9 : 8
`
`12:16 12 : 14
`
`12:20 13 : 7
`
`12:21 12 : 14
`
`1557 4:7,
`13,20
`
`1582 4:7,
`13,20
`
`2
`
`200 2:5
`4:15
`
`200IPR 4 : 5
`
`2017- 2 : 15
`
`3
`
`317 6:18
`10:21
`
`A
`
`abeyance
`6:24 7:17
`8:13
`
`accordance
`7 : 13
`
`adding
`11 : 11,12
`
`additional
`5:24 9:20
`10 : 8
`
`address 5 : 17
`10 : 13
`
`adjourn 13 : 6
`
`adjourns
`13 : 7
`
`advisement
`13 : 4
`
`affect
`
`6:15
`
`afternoon
`2:1,13,22
`3:18
`
`agree 3:3,22
`8:4 10:12
`
`ahead 10:4,
`24
`
`Alere 10 : 3
`
`appearance
`2 : 21
`
`appeared
`3 : 21
`
`appearing
`3 : 22
`
`applicable
`11 : 8
`
`argumentative
`11:20
`
`23 10:4,
`18,20,23
`11:21,22
`
`Board's 8:24
`
`arguments
`8:4 9:18
`
`both- -of
`5 : 20
`
`aspects
`
`6 : 8
`
`Brenda 3 : 8
`
`assume 12:7
`
`ATT 10:21
`
`attacks
`
`9:25
`
`authorization
`5:23
`
`authorized
`4 : 10
`
`aware 9 : 23
`
`B
`
`back 12 : 12
`
`back-up 2 : 5
`
`basis
`7:2
`
`6 : 5
`
`beginning
`10 : 9
`
`behalf 3:19
`8:8
`
`bit 11:11,
`12
`
`Board 6:19,
`22 7:14,
`15,24
`8:12,18
`9:9,14,19,
`
`briefing
`5 : 24 12 : 4
`
`Broma 2 : 4
`
`C
`
`call
`2:7,
`17,24 3:1,
`3,11,23
`4:3 5:22
`12:17
`
`case 2:16
`3:2 4:15
`5:20 8:20
`10:3,6
`11:8,14,19
`
`cases 4:16,
`23 5:24
`8:25 9:17
`10:18
`
`challenge
`7 : 19
`
`change 5 : 25
`
`changed 4 : 16
`
`circumstances
`5 : 25
`
`City 10 : 19
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0016
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: clarification-experts
`
`clarification
`4:5 5:1
`
`considered
`9:19
`
`decided
`11:11
`
`clarify
`4:19
`
`2:23
`
`clear 6:10
`7:9
`
`co-counsel
`2:5
`
`colleague
`3:20
`
`continue
`7:20
`
`continued
`8:1
`
`continuing
`8:3
`
`Convergent
`10:22
`
`combined 2:7
`3:3, 1 0
`
`coordinated
`6:11
`
`1
`
`: 9
`
`copied 7:7
`
`copy 2:10
`
`correct
`6:18
`
`4:25
`
`counsel 2:2,
`5,14 3:7
`10:9
`
`comment
`12:9
`
`comments
`7:22,24
`10:12,15
`
`committed
`8 : 3
`
`complaints
`10:25
`
`decides 9:9
`
`decides --if
`9:9
`
`deciding 9:9
`
`decision
`7:17 8:12,
`24 10:1
`
`decision --or
`9:4
`
`decisions
`9:5 10:2
`
`delay 8:24
`9:20 10:5
`11:1
`
`deny 7 : 18
`
`depending
`5:22
`
`court 2:3,18
`3:9,24
`
`deposition
`7:10
`
`confer 12:12
`
`current
`
`9:1
`
`didn' t 12:1
`
`6:20 8:11
`11:24,25
`12:6
`
`don' t 5:6, a
`7 : 9
`
`due 5:25
`8:25 9:1,
`3,4,6 11:2
`
`Dustin 2 : 4
`5:16,18
`8:7,11
`12:20
`
`E
`
`early 10:1
`
`email 5:12
`11:21
`
`entirety
`8:18
`
`essentially
`7:7
`
`evidence 7:7
`
`excusing
`6:25
`
`exercise
`6:23 7:16
`
`exercised
`7 : 25
`
`exercises
`10:20
`
`expert
`
`7 : 8
`
`conference
`4:3
`
`conferred
`13:2
`
`confirm
`12:16
`
`D
`
`Danek 3 : 8
`
`date
`
`9 : 3,4
`
`dates
`
`9 : 1, 6
`
`confirmation
`3:2
`
`December
`8:25
`
`Congress
`6:23
`
`decide 10:5
`11:22
`
`difference
`11:14
`
`direct
`
`4 : 4
`
`discretion
`6:19,20,23
`7:16,24,25
`10:20
`
`discussion
`2:20
`
`doesn't
`
`4 : 23
`
`experts
`
`7 : 8
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0017
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: explain..Ira
`
`explain
`
`6 : 4
`
`extent
`10 : 13
`
`2 : 19
`
`F
`
`fact 7 : 24 ,
`25 11 : 4
`
`factors
`
`7 : 14
`
`facts 10 : 23
`11 : 21
`
`2:10
`file
`3:9 7:13
`9:2 11:16,
`23
`
`4 : 10
`filed
`5:21 7:5
`9 : 16 11 : 6 ,
`16
`
`3 : 24
`filing
`4:12 8:23
`
`fold
`
`7 : 12
`
`follow-on
`9 : 24
`
`followup
`10 : 18
`
`forced 9 : 15
`
`forward 5:9,
`10
`
`Fox 2:1,2,
`8,11 5:15
`8:5 12:18,
`19
`
`FRANKLIN
`2:6,9,12,
`23 3:5,12,
`16 4:1,18,
`25 5:11
`6:2 7:2,21
`8:5,10
`10:7,16
`12:7,11,
`15,21,23,
`25 13:2
`
`Frederickson
`3 : 21
`
`front 11 : 21
`
`future
`
`8 : 20
`
`G
`
`gave 6:23
`
`General 10 : 1
`11 : 7
`
`give 5 : 13
`6:3
`
`Good 2:1,13
`3:6,18
`
`Goodwin 3 : 19
`
`grant
`
`6 : 24
`
`granted 8:2
`10 : 24
`
`granting
`10 : 21
`
`grants
`
`7 : 14
`
`Great 13 : 2
`
`guess 2 : 16
`5 : 22
`
`insisting
`11:2
`
`H
`
`harassment
`9 : 24
`
`Harold 2:1,
`2,8,11
`5:15
`12:18,19
`
`hearing 9 : 7
`10:25 13:7
`
`hold 6:24
`7:16 8:12
`12:12
`
`holding 8 : 19
`12 : 15
`
`Honor 2:1,13
`3:4,6,14,
`18 4:14,22
`5:15, 18
`6:9,16
`7:4,23 8:7
`10:11,17
`11:9 12:5,
`10,20,22,
`24 13:1
`
`hook 6 : 21
`
`I
`
`impression
`2 : 17
`
`indicating
`13 : 5
`
`instituting
`9:19
`
`institution
`8:24 9 : 4,5
`
`interest
`7:19
`
`invited
`
`2 : 24
`
`involved
`2 : 17
`
`involves
`2 : 19
`
`IPR 6:19
`9:1,20,21
`
`IPR200 2:25
`4:10 5:4,9
`6:6 8:14
`
`IPR2016-01155
`10:20
`
`IPR2017-01237
`10:22
`
`IFR2017-01557
`2:25
`
`IPR2017-01582
`3:20
`
`2 : 3
`IPR' S
`8:1 9:6
`10:14
`
`Ira 3:18,19
`7:23 12:10
`13:1
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0018
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: IRP-opposition
`
`IRP
`
`9
`
`: 7
`
`11:4,24
`
`limited 2 : 21
`
`long 11 : 4
`
`M
`
`made 9 : 13
`
`make
`6 : 10
`11 : 24 12 : 1 .
`
`Mylan 2:12,
`15 4:4,9,
`12 6:1,21,
`25 8:13,22
`9:1,2,7,20
`10:10,13
`
`N
`
`making 7 : 2
`
`named 2 : 3
`
`matter 13 : 3
`
`nature
`
`2 : 21
`
`mention 9 : 14 necessarily
`4 : 24
`
`needed 11 : 22
`
`note 8 : 21
`
`noted 11 : 20
`
`0
`
`object
`
`3 : 10
`
`occurred
`7 : 11
`
`opportunity
`5:13 6:4
`
`oppose 4:8,
`12,20 5:19
`6:6,16
`11:3 12:1
`
`opposed 11 : 5
`12 : 2
`
`opposes 9:12
`
`opposing
`5:24
`
`opposition
`
`IRP200
`
`4:20
`
`j oinders
`4:16
`
`7:8
`isn't
`8:25 11:8, joined 3 : 20
`19
`
`joins
`
`9 : 11
`
`joint
`
`3 : 23
`
`Jonathan
`3:6,7,14
`6:8,9 7:4
`10:17
`12:24
`
`issue
`
`5 : 3,6
`
`issued 10 : 1
`
`issues 6:14
`8:15 13:5
`
`2:10
`it's
`7:6 11:9,
`14
`
`I'd 4:3
`10:7
`
`8:8
`I'll
`12:12
`
`I'm 2:9 3:2
`4:18 9:22
`10:25
`12:12
`
`I've 13:2
`
`JUDGE 2:6,9, meritorious
`7 : 19
`12,23 3:5,
`12,16 4:1,
`18,25 5:11
`6:2 7:2,21
`8:5,10
`10:7,16
`12:7,11,
`15,21,23,
`25 13:2
`
`met 7 : 15
`
`Microsoft
`10:19
`
`momentarily
`12 : 13
`
`Monosol 2:2
`4:9 8:13
`10:14
`
`L
`
`months 8 : 22
`
`J
`
`late 8:25
`
`morning 3 : 6
`
`January 9:8
`
`lays 7:5
`
`join 3:22
`7:23 8:4
`12:8
`
`joinder 4:7,
`12,20 5:3,
`7,20,22,25
`6:13 7:5,
`6,15 8:2
`10:24
`
`lead
`
`2:2,14
`
`let's
`
`6:2
`
`Levy 3:18,
`19 7:21,23
`12:8,10,25
`13:1
`
`likewise
`10 : 21
`
`motion 4:10
`5:21 6:6,
`13,24,25
`7:4 8:12,
`18 9:10
`10:5 11:3,
`24
`
`motions
`11 : 17
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0019
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: oral..raised
`
`5:21 11:3
`
`oral 9:7
`11:17
`
`order 9:13
`13:4
`
`original
`6 : 21
`
`our- -which
`11 : 25
`
`overwhelmed
`11 : 13
`
`Owner 3:9,24
`5:11,16,
`19,23
`6:17,20
`7:17 8:8,
`9,11,17
`9:12,14,
`16,22
`11:2,5,12,
`15,20,23
`12:2
`
`Owners 10 : 25
`
`Owner' s 7 : 10
`
`P
`
`p.m. 12:14
`13:7
`
`panel 9:22
`12:12 13:3
`
`Par 3:5,7,
`23 4:2
`5:3,20,22
`6:3,10
`
`8:21 9:5,
`11,17,21
`12:6
`
`11:2,5,12,
`15,20,23
`12 : 2
`
`Pardon 6 : 9
`
`pending 6:19
`
`Parmelee
`2:13,14
`3:4 4:14,
`21 5:5
`10:11
`12:21,22
`
`Parrot 10 : 3
`
`part 10 : 21
`
`partially
`6:24
`
`participate
`2:7,19
`
`participation
`3 : 1 7 : 1
`
`parties
`2:23,24
`8:14,19
`12:11,16
`
`party 10:8
`
`petition 7:7
`8:2,22,23
`9:3 11:16,
`22
`
`petitioner
`2:12,14
`3:5,7,16
`4:4 6:10
`11:10 12:5
`
`petitioners
`4:2 5:7
`6:3,21
`10:8
`
`petitions
`5 : 7 9 : 24
`11:9
`
`picking
`11 : 10
`
`Plastics
`10 : 1 11 : 8
`
`passed 9:2,7
`11:4
`
`point 4:5
`5:17
`
`patent 3:9,
`24 5:11,
`16,19,23
`6:17,20
`7:10,17,20
`8:8,9,11,
`17 9:11,
`14,16,22,
`25 10:25
`
`points 11 : 7
`
`POR 11:15
`
`position
`4:16 5:2,
`5,12 6:22
`
`practice
`11 : 18
`
`prejudice
`8 : 19 9 : 22
`
`preliminary
`9:16,17
`11:5 12:3
`
`presented
`9 : 18
`
`presenting
`5 : 16
`
`previously
`5 : 6 9 : 19
`
`proceeding
`2:20,24
`4:11,22
`5:8 8:17
`
`proceedings
`2 : 5 3 : 22
`8 : 1
`
`proposes
`9 : 17
`
`public 7 : 9 ,
`19
`
`Q
`
`question 4 : 4
`5 : 14 6 : 5 ,
`16
`
`questions
`12 : 5
`
`R
`
`raised 13 : 5
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0020
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: reached..the--Pm
`
`reached 4 : 9
`8:14
`
`resolving
`9 : 20
`
`reason 7 : 18
`9 : 10
`
`reasons 7 : 6
`10 : 4
`
`recently
`9 : 23
`
`record 6:11
`7 : 9 12 : 14
`
`record- - to
`6:10
`
`Reddy 9 : 17
`
`Reddy' s
`3:17,19
`4:2 5:4,20
`6:3,11
`8:21 9:6,
`11,21
`
`repeated
`9 : 25
`
`reply 7 : 13
`9:3 11 : 17
`
`reporter
`2 : 3,18
`3 : 9,24
`
`4 : 12
`request
`6:4 7 : 3
`
`requesting
`9:21
`
`resolve 13 : 5
`
`resolved
`8:15
`
`respect
`
`4 : 7
`
`respond 5:13
`8 : 6,8
`
`response
`7:10 11:5,
`7 12 : 3
`
`responses
`9 : 16,18
`11 : 14
`
`responsibility
`5:8
`
`Robert 3 : 20
`
`6 : 12
`
`role
`8:3
`
`rush 9 : 15
`
`S
`
`S - t -r- a-n-
`3 : 14
`
`schedule
`7 : 13,14
`11 : 1,19
`
`scheduling
`9 : 13 11 : 1
`
`Section
`
`6 : 18
`
`seeking 3:2
`
`sense 11 : 24
`12 : 1
`
`September
`10:2
`
`serial
`
`11 : 9
`
`23,24
`
`settlement
`4:9,11 6:1
`8:14
`
`Sharon 2 : 4
`
`shortly 13 : 4
`
`shouldn' t
`9 : 15
`
`significant
`9 : 12
`
`similar
`10 : 19
`
`3 : 23
`
`situations
`10 : 19
`
`speak 6 : 14
`
`specifically
`10 : 14
`
`spell
`
`3 : 12
`
`Strang' s
`7:22
`
`strong
`
`9 : 23
`
`Subject 12 : 5
`
`submit 5 : 24
`8:17
`
`subsequent
`10:2
`
`subsequently
`8 : 16
`
`sur- reply
`11:23,25
`
`T
`
`talk
`
`4 : 2,15
`
`Technologies
`2 : 15
`
`stance
`
`9 : 23
`
`telling
`
`4:19
`
`start
`
`6 : 5
`
`stated
`
`5 : 6
`
`6 : 12 ,
`
`stay
`13
`
`Steve 2:13,
`14 3:4
`4:14,21
`5:5 10:11
`12:22
`
`Strang 3 : 6,
`7,14 6:8,9
`7:4 10:16,
`17 12 : 8 ,
`
`terminate
`4:11 6:6,
`25 8:13,16
`9:10 10:5
`
`terminated
`4:22 5 : 8
`
`termination
`2:20 4:15,
`24 5 : 2
`10:13
`
`2 :21
`that' s
`8:9 10:22
`
`the--i'm
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte - Atlanta - Washington, DC - New York - Houston - San Francisco
`
`Par v. MonoSol
`IPR2017-01557
`
`MonoSol2005-0021
`
`
`
`MYLAN PHARMACEUTICAL INC. v. MONOSOL RX, LLC
`Hearing on 10/04/2017
`Index: the--we-You're
`
`2 : 16
`
`the --we 6 : 22
`
`6 : 8
`there' s
`12 : 3 13 : 6
`
`they' d 6 : 13
`
`unfairness
`11 : 10
`
`Y
`
`urgently
`
`4 : 3
`
`You're 4 : 19
`
`V
`
`they're
`
`6 : 12
`
`view 4 : 11
`
`they've
`12 : 2
`
`8 : 15
`
`time 5 : 1
`9 : 3,4 11 : 3
`
`timely 7 : 5
`
`timing 6 : 7 ,
`18
`
`today 3 : 8
`5 : 23 13 : 5
`
`transcript
`2:10 3:10,
`25 7:11,12
`
`treated
`
`4 : 23
`
`4 : 24
`
`turn
`6 : 2
`
`U
`
`ultimately
`9 : 11
`
`undecided
`8 : 20
`
`understand
`3 : 23 4 : 8
`5 : 12
`
`understudy
`6 : 12 8 : 3
`
`W
`
`wait 9 : 9
`
`waited 8 : 22
`
`wanted 4 : 25
`
`wanting 6 : 6
`
`we--a
`
`7 : 10
`
`week 10 : 3
`
`weeks 2 : 4
`5:16,18,19
`8 : 7,8,11
`9 : 8 10 : 12
`12:18,20
`
`weren' t
`
`9 : 18
`
`we'd 4:21
`
`7 : 12
`we'll
`8:21 13:5
`
`we're 2:15,
`18 4 : 14
`7 : 11,15
`11 : 16 13 : 3
`
`we've
`
`6 : 11
`
`Windy 10 : 19
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte — Atlanta — Washington, DC — New York — Houston — San Francisco
`
`Pa
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
